254 related articles for article (PubMed ID: 20713771)
1. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression.
Samimi S; Benoit B; Evans K; Wherry EJ; Showe L; Wysocka M; Rook AH
Arch Dermatol; 2010 Dec; 146(12):1382-8. PubMed ID: 20713771
[TBL] [Abstract][Full Text] [Related]
2. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
[TBL] [Abstract][Full Text] [Related]
4. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
López-Lerma I; Estrach MT
J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD164 on Malignant T cells in Sézary Syndrome.
Guenova E; Ignatova D; Chang YT; Contassot E; Mehra T; Saulite I; Navarini AA; Mitev V; Dummer R; Kazakov DV; French LE; Hoetzenecker W; Cozzio A
Acta Derm Venereol; 2016 May; 96(4):464-7. PubMed ID: 26524186
[TBL] [Abstract][Full Text] [Related]
8. TIGIT and Helios Are Highly Expressed on CD4
Jariwala N; Benoit B; Kossenkov AV; Oetjen LK; Whelan TM; Cornejo CM; Takeshita J; Kim BS; Showe LC; Wysocka M; Rook AH
J Invest Dermatol; 2017 Jan; 137(1):257-260. PubMed ID: 27592800
[No Abstract] [Full Text] [Related]
9. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma.
Shimauchi T; Kabashima K; Nakashima D; Sugita K; Yamada Y; Hino R; Tokura Y
Int J Cancer; 2007 Dec; 121(12):2585-90. PubMed ID: 17721918
[TBL] [Abstract][Full Text] [Related]
10. Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping.
Pulitzer MP; Horna P; Almeida J
Cytometry B Clin Cytom; 2021 Mar; 100(2):132-138. PubMed ID: 32516521
[TBL] [Abstract][Full Text] [Related]
11. PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome.
Lewis NE; Gao Q; Petrova-Drus K; Pulitzer M; Sigler A; Baik J; Moskowitz AJ; Horwitz SM; Dogan A; Roshal M
Cytometry B Clin Cytom; 2022 May; 102(3):189-198. PubMed ID: 35451196
[TBL] [Abstract][Full Text] [Related]
12. IgG anti-50 kd lymphocyte membrane peptide antibody in patients with Sézary syndrome.
D'Ambra-Cabry K; Tharp MD; Jagasothy BV; Deng JS
J Am Acad Dermatol; 1996 May; 34(5 Pt 1):777-80. PubMed ID: 8632073
[TBL] [Abstract][Full Text] [Related]
13. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
Front Immunol; 2020; 11():579894. PubMed ID: 33072126
[TBL] [Abstract][Full Text] [Related]
14. The role of 9-O-acetylated ganglioside D3 (CD60) and {alpha}4{beta}1 (CD49d) expression in predicting the survival of patients with Sezary syndrome.
Scala E; Abeni D; Pomponi D; Narducci MG; Lombardo GA; Mari A; Frontani M; Picchio MC; Pilla MA; Caprini E; Russo G
Haematologica; 2010 Nov; 95(11):1905-12. PubMed ID: 20663947
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
16. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
Durgin JS; Jariwala NN; Wysocka M; Zhang KK; Maity A; Benoit B; Plastaras JP; Lewis DJ; Rosenthal JM; Teague JE; Berg S; Del Guzzo C; Kim EJ; Vittorio C; Haun PL; Samimi SS; Villasenor-Park J; Inverso J; Clark RA; Rook AH
JAMA Dermatol; 2021 Jan; 157(1):90-95. PubMed ID: 33112366
[TBL] [Abstract][Full Text] [Related]
17. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome.
Sokolowska-Wojdylo M; Wenzel J; Gaffal E; Steitz J; Roszkiewicz J; Bieber T; Tüting T
Clin Exp Dermatol; 2005 Nov; 30(6):702-6. PubMed ID: 16197392
[TBL] [Abstract][Full Text] [Related]
18. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction.
D'Souza M; Fontenot AP; Mack DG; Lozupone C; Dillon S; Meditz A; Wilson CC; Connick E; Palmer BE
J Immunol; 2007 Aug; 179(3):1979-87. PubMed ID: 17641065
[TBL] [Abstract][Full Text] [Related]
19. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
[TBL] [Abstract][Full Text] [Related]
20. Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome.
Di Raimondo C; Rubio-Gonzalez B; Palmer J; Weisenburger DD; Zain J; Wu X; Han Z; Rosen ST; Song JY; Querfeld C
Br J Dermatol; 2022 Aug; 187(2):234-243. PubMed ID: 35194801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
